Environmental Tectonics Corporation's BioMedical Systems Division Announces Additional Sales of its Baramed Monoplac...(me to time by or on behalf of the Compan...),Health
Navigation Links
Environmental Tectonics Corporation's BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
Date:11/20/2008
me to time by or on behalf of the Company.
Contact: Duane D. Deaner, CFO,
Tel: 215-355-9100 (ext. 1203)
Fax: 215-357-4000
ETC - Internet Home Page:http://www.etcusa.com
'/>"/>
| SOURCE Environmental Tectonics Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Environmental and Technology Firm Integral Consulting Inc. Expands Services, Launches New Website
2. Cornell researchers study showing evidence of a major environmental trigger for autism
3. AMA Journal Publishes Study Showing Evidence of a Major Environmental Trigger For Autism
4. Environmental Tectonics Corporations Sterilization Systems Group Announces the Receipt of Three New Contracts
5. Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do Careful Study of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO
6. Filters Fast Advocates Use of Filtered Water Bottles for Environmental and Personal Health
7. Caribbean Sol Biodegradable Sunscreen Gets Strong Safety Rating From Environmental Working Group
8. Homosexual behavior due to genetics and environmental factors
9. Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality
10. Environmental Tectonics Corporation Announces Sale of Two Hyperbaric Monoplace Chambers
11. Premier issue of Environmental Justice just published
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges' 2Health News:Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools 2Health News:Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools 3Health News:Some Myths About Dogs and Cats Are Not Only False - They're Dangerous! 2Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 2Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 3Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 2Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 3Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 4Health News:U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it 5
[0] Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges'[0] Independence Blue Cross Supports Pennsylvania Fitness Program with Grants to 10 Area Schools[0] Some Myths About Dogs and Cats Are Not Only False - They're Dangerous![0] Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009[0] U.S. Bishops Urge Senators to Support Nelson-Hatch-Casey Amendment on Health Care Reform; Urge Constituents to Back it
Other Medicine News:Health News:QHR Management Client Hancock Medical Center Named Mississippi Hospital of the Year 2Health News:Sales Force Effectiveness: Less Texting, More Engagement 2Health News:For All Their Plusses, Pets Pose a Risk for Falls, Too 2Health News:For All Their Plusses, Pets Pose a Risk for Falls, Too 3Health News:GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act' 2
QHR Management Client Hancock Medical Center Named Mississippi Hospital of the YearHouse-Passed Legislation Crafted to Line the Pockets of Personal Injury Lawyers, Says Michigan Chamber of CommerceSales Force Effectiveness: Less Texting, More EngagementFor All Their Plusses, Pets Pose a Risk for Falls, TooGPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act'Diabetics May Soon Have Low-Sugar Vegetable Juice
Breaking Medicine Technology:Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Beverage Can Stay Tabs Pose Swallowing Risk 62223 1Beverage Can Stay Tabs Pose Swallowing Risk 62223 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 1New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 2New Class of Platinum Based Anti Tumor Drugs Bisplatinates Demonstrates Potent Anti Tumor Activity and Ability to Overcome Resistance to Currently A 14993 3Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 1Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 2Elsevier is Re Launching 26quot 3BEmbase 26quot 3B to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 14989 3
Other Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |